Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Higher-than-normal levels of circulating triglycerides are a risk factor for ischemic cardiovascular disease. Activation of lipoprotein lipase, an enzyme that is inhibited by angiopoietin-like 4 (ANGPTL4), has been shown to reduce levels of circulating triglycerides. METHODS: We sequenced the exons of ANGPTL4 in samples obtain from 42,930 participants of predominantly European ancestry in the DiscovEHR human genetics study. We performed tests of association between lipid levels and the missense E40K variant (which has been associated with reduced plasma triglyceride levels) and other inactivating mutations. We then tested for associations between coronary artery disease and the E40K variant and other inactivating mutations in 10,552 participants with coronary artery disease and 29,223 controls. We also tested the effect of a human monoclonal antibody against ANGPTL4 on lipid levels in mice and monkeys. RESULTS: We identified 1661 heterozygotes and 17 homozygotes for the E40K variant and 75 participants who had 13 other monoallelic inactivating mutations in ANGPTL4. The levels of triglycerides were 13% lower and the levels of high-density lipoprotein (HDL) cholesterol were 7% higher among carriers of the E40K variant than among noncarriers. Carriers of the E40K variant were also significantly less likely than noncarriers to have coronary artery disease (odds ratio, 0.81; 95% confidence interval, 0.70 to 0.92; P=0.002). K40 homozygotes had markedly lower levels of triglycerides and higher levels of HDL cholesterol than did heterozygotes. Carriers of other inactivating mutations also had lower triglyceride levels and higher HDL cholesterol levels and were less likely to have coronary artery disease than were noncarriers. Monoclonal antibody inhibition of Angptl4 in mice and monkeys reduced triglyceride levels. CONCLUSIONS: Carriers of E40K and other inactivating mutations in ANGPTL4 had lower levels of triglycerides and a lower risk of coronary artery disease than did noncarriers. The inhibition of Angptl4 in mice and monkeys also resulted in corresponding reductions in these values. (Funded by Regeneron Pharmaceuticals.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Similarly, inactivating variants in ANGPTL4, a key inhibitor of LPL, have been shown to reduce levels of TGs, LDL-C, and HDL-C. Individuals with these variants exhibit lifelong reductions in circulating TGs and up to a 19% lower risk of CAD [26].”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [26]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“rare loss-of-function mutations in the lipoprotein lipase (LPL) gene are associated with higher plasma triglyceride levels and a higher risk of cardiovascular disease”
From Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease (2019) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“while rare, loss-of-function mutations in the APOC3, ANGPTL3, and ANGPTL4 genes, which encode for natural inhibitors of LPL, are associated with lower triglyceride levels and a corresponding lower risk of cardiovascular disease.[9][10][11][12][13]”
From Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease (2019) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Like mice, humans deficient in ANGPTL3, ANGPTL4, or ANGPTL8 have lower plasma triglycerides (56–58, 163–166).”
From Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8 (2021) · cites this paper as [56]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Mendelian randomization studies focused on variants in the genes encoding apoAV, apoCIII, lipoprotein lipase (LpL) and the angiopoietin-like proteins 3, 4, and 8 (ANGPTL3, ANGPTL4, and ANGPTL8) have been highly informative.29–35”
10 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895
Cingolani, P., Platts, A., Wang, L. L., Coon, M., Nguyen, T., Wang, L., Land, S. J., Lu, X., & Ruden, D. M. (2012) · Fly · doi:10.4161/fly.19695 · Cited by 11,816
GCTA: a tool for genome-wide complex trait analysis
Yang, J., Lee, S. H., Goddard, M. E., & Visscher, P. M. (2011) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2010.11.011 · Cited by 8,279
Van der Auwera, G. A., Carneiro, M. O., Hartl, C., Poplin, R., del Angel, G., Levy‐Moonshine, A., Jordan, T., Shakir, K., Roazen, D., Thibault, J., et al. (2013) · Current Protocols in Bioinformatics · doi:10.1002/0471250953.bi1110s43 · Cited by 6,687
A solution to the problem of separation in logistic regression
Heinze, G., & Schemper, M. (2002) · Statistics in Medicine · doi:10.1002/sim.1047 · Cited by 2,711
Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association
Miller, M., Stone, N. J., Ballantyne, C., Bittner, V., Criqui, M. H., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Jacobson, M. S., Kris-Etherton, P. M., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182160726 · Cited by 1,871
Li, B., & Leal, S. M. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2008.06.024 · Cited by 1,527
Triglycerides and cardiovascular disease
Nordestgaard, B. G., & Varbo, A. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61177-6 · Cited by 1,419
Sarwar, N., Danesh, J., Eiriksdottir, G., Sigurdsson, G., Wareham, N., Bingham, S., Boekholdt, S. M., Khaw, K.-T., & Gudnason, V. (2007) · Circulation · doi:10.1161/circulationaha.106.637793 · Cited by 1,408
Research works printed but not linked: 2
- Van der Auwera GA, 2013, Curr Protoc Bioinformatics, 11, 11.10.1
- Romeo S, 2009, J Clin Invest, 119, 70
Cited by
Ginsberg, H. N., Packard, C. J., Chapman, M. J., Borén, J., Aguilar-Salinas, C. A., Averna, M., Ference, B. A., Gaudet, D., Hegele, R. A., Kersten, S., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab551 · Cited by 979
Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease
Dewey, F. E., Gusarova, V., Dunbar, R. L., O’Dushlaine, C., Schurmann, C., Gottesman, O., McCarthy, S., Van Hout, C. V., Bruse, S., Dansky, H. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612790 · Cited by 885
Self-citationRichardson, T. G., Sanderson, E., Palmer, T. M., Ala-Korpela, M., Ference, B. A., Davey Smith, G., & Holmes, M. V. (2020) · PLOS Medicine · doi:10.1371/journal.pmed.1003062 · Cited by 843
Ference, B. A., Kastelein, J. J. P., Ray, K. K., Ginsberg, H. N., Chapman, M. J., Packard, C. J., Laufs, U., Oliver-Williams, C., Wood, A. M., Butterworth, A. S., et al. (2019) · JAMA · doi:10.1001/jama.2018.20045 · Cited by 703
Mendelian randomization in cardiometabolic disease: challenges in evaluating causality
Holmes, M. V., Ala-Korpela, M., & Smith, G. D. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.78 · Cited by 679
Metabolic-associated fatty liver disease and lipoprotein metabolism
Heeren, J., & Scheja, L. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101238 · Cited by 646
“Angiopoietin-like proteins Three members of the angiopoietin-like (ANGPTL) family, ANGPTL3, ANGPTL4 and ANGPTL8, regulate peripheral TRL processing.”
BackgroundInfluentialGenetics of coronary artery disease: discovery, biology and clinical translation
Khera, A. V., & Kathiresan, S. (2017) · Nature Reviews Genetics · doi:10.1038/nrg.2016.160 · Cited by 659
Sandesara, P. B., Virani, S. S., Fazio, S., & Shapiro, M. D. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00184 · Cited by 608
“Similarly, carriers of the E40K variant in ANGPTL4 had a 19% lower risk of CAD compared to noncarriers (128).”
BackgroundGenetics of blood lipids among ∼300,000 multi-ethnic participants of the Million Veteran Program
Global Lipids Genetics Consortium, Klarin, D., Myocardial Infarction Genetics (MIGen) Consortium, The Geisinger-Regeneron DiscovEHR Collaboration, Program, T. V. M. V., Damrauer, S. M., Cho, K., Sun, Y. V., Teslovich, T. M., Honerlaw, J., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0222-9 · Cited by 625
Self-citationEPIC-InterAct Consortium, Lotta, L. A., Cambridge FPLD1 Consortium, Gulati, P., Day, F. R., Payne, F., Ongen, H., van de Bunt, M., Gaulton, K. J., Eicher, J. D., et al. (2017) · Nature Genetics · doi:10.1038/ng.3714 · Cited by 585
Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides
Graham, M. J., Lee, R. G., Brandt, T. A., Tai, L.-J., Fu, W., Peralta, R., Yu, R., Hurh, E., Paz, E., McEvoy, B. W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701329 · Cited by 573
Dysregulated lipid metabolism links NAFLD to cardiovascular disease
Deprince, A., Haas, J. T., & Staels, B. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101092 · Cited by 554
“Conversely, decreased plasma ANGPTL4, which is transcriptionally activated by peroxisome proliferator-activated receptor (PPAR) a, is also associated with carotid artery stenosis (vessel wall thickness measured by magnetic resonance imaging, MRI) [82], suggesting increased CVD risk.”
BackgroundInfluentialClinical review on triglycerides
Laufs, U., Parhofer, K. G., Ginsberg, H. N., & Hegele, R. A. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz785 · Cited by 544
“given an anti-ANGPTL4 antibody developed mesenteric adenitis, providing a cautionary note about pursuing this target in humans.(99)”
BackgroundDewey, F. E., Murray, M. F., Overton, J. D., Habegger, L., Leader, J. B., Fetterolf, S. N., O’Dushlaine, C., Van Hout, C. V., Staples, J., Gonzaga-Jauregui, C., et al. (2016) · Science · doi:10.1126/science.aaf6814 · Cited by 548
“Sample preparation and whole-exome sequencing were performed as described (55).”
MethodSelf-citationA Modern Approach to Dyslipidemia
Berberich, A. J., & Hegele, R. A. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab037 · Cited by 469
Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease
Myocardial Infarction Genetics and CARDIoGRAM Exome Consortia Investigators (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1507652 · Cited by 493
“The identification by Dewey et al.16 of additional ANGPTL4 inactivating mutation carriers, now reported in the Journal, provides further evidence of the association between a loss of ANGPTL4 function and lower triglyceride levels and a reduced risk of coronary artery disease.”
BackgroundDrug development in the era of precision medicine
Dugger, S. A., Platt, A., & Goldstein, D. B. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.226 · Cited by 493
ANGPTL3 deficiency and protection against coronary artery disease
Stitziel, N. O., Khera, A. V., Wang, X., Bierhals, A. J., Vourakis, A. C., Sperry, A. E., Natarajan, P., Klarin, D., Emdin, C. A., Zekavat, S. M., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.02.030 · Cited by 467
“This study adds ANGPTL3 to the list of therapeutic targets for coronary disease, which includes ANGPTL4 (16,36), APOC3 (11,37), LPA (38), NPC1L1 (30), and PCSK9 (39), that have been validated by finding LOF mutations that associate with protection from disease, Association of ANGPTL3 Concentration With MI Risk in PROM…”
BackgroundInfluentialRoden, D. M., McLeod, H. L., Relling, M. V., Williams, M. S., Mensah, G. A., Peterson, J. F., & Van Driest, S. L. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31276-0 · Cited by 427
Genetic identification of familial hypercholesterolemia within a single U.S. health care system
Abul-Husn, N. S., Manickam, K., Jones, L. K., Wright, E. A., Hartzel, D. N., Gonzaga-Jauregui, C., O’Dushlaine, C., Leader, J. B., Lester Kirchner, H., Lindbuchler, D. M., et al. (2016) · Science · doi:10.1126/science.aaf7000 · Cited by 425
“Sample preparation andwhole exome sequencing were performed at the RGC as previously described (25).”
BackgroundMethodInfluentialSelf-citationHypertriglyceridaemia and risk of coronary artery disease
Reiner, Ž. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.31 · Cited by 387
Personalized Medicine and the Power of Electronic Health Records
Abul-Husn, N. S., & Kenny, E. E. (2019) · Cell · doi:10.1016/j.cell.2019.02.039 · Cited by 355
“We can expect that EHR-linked biobanks will increasingly be used in genomics-driven drug discovery (Abul-Husn et al., 2018; Dewey et al., 2016a; Myocardial Infarction Genetics and CARDIoGRAM Exome Consortia Investigators et al., 2016) and drug repurposing.”
BackgroundProbiotics, prebiotics, synbiotics and insulin sensitivity
Kim, Y. A., Keogh, J. B., & Clifton, P. M. (2018) · Nutrition Research Reviews · doi:10.1017/s095442241700018x · Cited by 335
“A very recent study showed that inhibition of or a lower level of ANGPTL4 is associated with lower risk of CVD in mice and non-human primate models (142) .”
BackgroundFrąk, W., Wojtasińska, A., Lisińska, W., Młynarska, E., Franczyk, B., & Rysz, J. (2022) · Biomedicines · doi:10.3390/biomedicines10081938 · Cited by 303
“The opposite effect is shown by mutations in the APOC3 and ANGPTL4 genes, which are responsible for the inhibition of lipoprotein lipase [62,63].”
BackgroundA decade of genome-wide association studies for coronary artery disease: the challenges ahead
Erdmann, J., Kessler, T., Munoz Venegas, L., & Schunkert, H. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy084 · Cited by 325
Pradhan, A. D., Paynter, N. P., Everett, B. M., Glynn, R. J., Amarenco, P., Elam, M., Ginsberg, H., Hiatt, W. R., Ishibashi, S., Koenig, W., et al. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.09.011 · Cited by 319
Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia
Borén, J., Taskinen, M.-R., Björnson, E., & Packard, C. J. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00676-y · Cited by 315
Richardson, T. G., Leyden, G. M., Wang, Q., Bell, J. A., Elsworth, B., Davey Smith, G., & Holmes, M. V. (2022) · PLOS Biology · doi:10.1371/journal.pbio.3001547 · Cited by 304
Understanding Society Scientific Group, Wain, L. V., Geisinger-Regeneron DiscovEHR Collaboration, Shrine, N., Artigas, M. S., Erzurumluoglu, A. M., Noyvert, B., Bossini-Castillo, L., Obeidat, M., Henry, A. P., et al. (2017) · Nature Genetics · doi:10.1038/ng.3787 · Cited by 288
Self-citationHepatokines and metabolism: Deciphering communication from the liver
Jensen-Cody, S. O., & Potthoff, M. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101138 · Cited by 252
Genetics of Common, Complex Coronary Artery Disease
Musunuru, K., & Kathiresan, S. (2019) · Cell · doi:10.1016/j.cell.2019.02.015 · Cited by 239
ANGPTL4 in Metabolic and Cardiovascular Disease
Aryal, B., Price, N. L., Suarez, Y., & Fernández-Hernando, C. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.05.010 · Cited by 234
“Unfortunately, atherogenic diets rich in saturated fats have several undesirable effects in mice and monkeys lacking ANGPTL4 [49, 50, 52, 85].”
BackgroundInfluentialManagement of hypertriglyceridemia
Simha, V. (2020) · BMJ · doi:10.1136/bmj.m3109 · Cited by 223
Lipoprotein lipase and its regulators: an unfolding story
Wu, S. A., Kersten, S., & Qi, L. (2021) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.11.005 · Cited by 225
“Several genome-wide association (GWAS) studies have identified a loss-of-function variant of human ANGPTL4 with Glu40-to-Lys substitution (E40K) in the coiled-coil domain which is associated with lower serum triglycerides and reduced risk of coronary artery disease (Figure 1f) [60].”
BackgroundXiao, C., Dash, S., Morgantini, C., Hegele, R. A., & Lewis, G. F. (2016) · Diabetes · doi:10.2337/db16-0046 · Cited by 212
“The inhibition of ANGPTL4 with antibody reduced serum TG levels in mice and monkeys (105).”
BackgroundAdam, R. C., Mintah, I. J., Alexa-Braun, C. A., Shihanian, L. M., Lee, J. S., Banerjee, P., Hamon, S. C., Kim, H. I., Cohen, J. C., Hobbs, H. H., et al. (2020) · Journal of Lipid Research · doi:10.1194/jlr.ra120000888 · Cited by 208
Self-citationANGPTL8 requires ANGPTL3 to inhibit lipoprotein lipase and plasma triglyceride clearance
Haller, J. F., Mintah, I. J., Shihanian, L. M., Stevis, P., Buckler, D., Alexa-Braun, C. A., Kleiner, S., Banfi, S., Cohen, J. C., Hobbs, H. H., et al. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m075689 · Cited by 199
Self-citationAssociation of rare and common variation in the lipoprotein lipase gene with coronary artery disease
Khera, A. V., Won, H.-H., Peloso, G. M., O’Dushlaine, C., Liu, D., Stitziel, N. O., Natarajan, P., Nomura, A., Emdin, C. A., Gupta, N., et al. (2017) · JAMA · doi:10.1001/jama.2017.0972 · Cited by 198
“Remnant cholesterol 33 (23-48) 28 (19-40) 33 (22-50) 24 (16-35)”
Self-citationUnmet Need for Adjunctive Dyslipidemia Therapy in Hypertriglyceridemia Management
Ganda, O. P., Bhatt, D. L., Mason, R. P., Miller, M., & Boden, W. E. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.04.061 · Cited by 195
“similarly strong association has been reported with monogenic variants involving lipoprotein lipase (22), apolipoprotein (apo) A5 (23), apo CII (24), apo CIII (23,25,26), angiopoietin-like protein (ANGPTL) 3 (25,27,28), andANGPTL4 (29).”
BackgroundTriglycerides and Triglyceride-Rich Lipoproteins in the Causal Pathway of Cardiovascular Disease
Budoff, M. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.04.004 · Cited by 184
Big Data Analytics for Genomic Medicine
He, K., Ge, D., & He, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020412 · Cited by 178
“For instance, a study conducted by Regeneron Genetics Center and the Geisinger Health System has highlighted the value of integrating genomic data and EHRs to uncover a genetic variant that results in reduced levels of triglycerides and a lower risk of coronary artery disease [119].”
ResultHeine, M., Fischer, A. W., Schlein, C., Jung, C., Straub, L. G., Gottschling, K., Mangels, N., Yuan, Y., Nilsson, S. K., Liebscher, G., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.06.020 · Cited by 182
Balling, M., Afzal, S., Varbo, A., Langsted, A., Davey Smith, G., & Nordestgaard, B. G. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.09.610 · Cited by 175
Lipid-Lowering Agents: Targets Beyond PCSK9
Hegele, R. A., & Tsimikas, S. (2019) · Circulation Research · doi:10.1161/circresaha.118.313171 · Cited by 171
“treated with an anti-ANGPTL4 antibody, which would temper enthusiasm for developing this agent.(156)”
Basu, D., Huggins, L.-A., Scerbo, D., Obunike, J., Mullick, A. E., Rothenberg, P. L., Di Prospero, N. A., Eckel, R. H., & Goldberg, I. J. (2018) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.118.311339 · Cited by 163
ANGPTL4: a multifunctional protein involved in metabolism and vascular homeostasis
Fernández-Hernando, C., & Suárez, Y. (2020) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000580 · Cited by 161
“Thus, this mutation uncovers beneficial metabolic outcomes on different lipid parameters, including lower plasma TAGs and higher HDL-C levels compared r Health, Inc.”
BackgroundInfluentialLuo, F., Das, A., Chen, J., Wu, P., Li, X., & Fang, Z. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0860-y · Cited by 163
Jurgens, S. J., Choi, S. H., Morrill, V. N., Chaffin, M., Pirruccello, J. P., Halford, J. L., Weng, L.-C., Nauffal, V., Roselli, C., Hall, A. W., et al. (2022) · Nature Genetics · doi:10.1038/s41588-021-01011-w · Cited by 170
“Our analysis revealed several genes that have been proposed as potential therapeutic targets or for which lipid-lowering therapeutics are in development, such as ANGPTL3 34 , ANGPTL4 35 and PCSK9 16-18 .”
Self-citationRegulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8
Sylvers-Davie, K. L., & Davies, B. S. J. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00195.2021 · Cited by 154
Genomics-First Evaluation of Heart Disease Associated With Titin-Truncating Variants
Haggerty, C. M., Damrauer, S. M., Levin, M. G., Birtwell, D., Carey, D. J., Golden, A. M., Hartzel, D. N., Hu, Y., Judy, R., Kelly, M. A., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.039573 · Cited by 158
Self-citationAddressing dyslipidemic risk beyond LDL-cholesterol
Tall, A. R., Thomas, D. G., Gonzalez-Cabodevilla, A. G., & Goldberg, I. J. (2022) · Journal of Clinical Investigation · doi:10.1172/jci148559 · Cited by 150
“Reduced-function variants of ANGPTL4 have been associated with lower TG levels, increased HDL-C, and reduced CVD risk (120).”
BackgroundRole and mechanism of the action of angiopoietin-like protein ANGPTL4 in plasma lipid metabolism
Kersten, S. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100150 · Cited by 145
Gusarova, V., O’Dushlaine, C., Teslovich, T. M., Benotti, P. N., Mirshahi, T., Gottesman, O., Van Hout, C. V., Murray, M. F., Mahajan, A., Nielsen, J. B., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04611-z · Cited by 145
Self-citationChen, Y. Q., Pottanat, T. G., Siegel, R. W., Ehsani, M., Qian, Y.-W., Zhen, E. Y., Regmi, A., Roell, W. C., Guo, H., Luo, M. J., et al. (2020) · Journal of Lipid Research · doi:10.1194/jlr.ra120000781 · Cited by 147
“Our observations in this study are also consistent with the observed ANGPTL knockout phenotypes (74, 79, 103).”
Averna, M., Banach, M., Bruckert, E., Drexel, H., Farnier, M., Gaita, D., Magni, P., März, W., Masana, L., Mello e Silva, A., et al. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.03.039 · Cited by 137
GPIHBP1 and Lipoprotein Lipase, Partners in Plasma Triglyceride Metabolism
Young, S. G., Fong, L. G., Beigneux, A. P., Allan, C. M., He, C., Jiang, H., Nakajima, K., Meiyappan, M., Birrane, G., & Ploug, M. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.05.023 · Cited by 141
“The ANGPTL4E40K variant, present in 3% of Caucasians, is associated with lower plasma triglyceride levels and reduced risk of coronary disease (Dewey et al., 2016; Helgadottir et al., 2016; Investigators et al., 2016).”
BackgroundFruchart, J.-C., Santos, R. D., Aguilar-Salinas, C., Aikawa, M., Al Rasadi, K., Amarenco, P., Barter, P. J., Ceska, R., Corsini, A., Després, J.-P., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0864-7 · Cited by 140
Personalized Drug Therapy: Innovative Concept Guided With Proteoformics
Su, J., Yang, L., Sun, Z., & Zhan, X. (2024) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2024.100737 · Cited by 163
“While it is well-established that patients vary in their response to the same disease (1), a standardized approach is frequently applied in the diagnostic and treatment processes (2).”
BackgroundAbsence of ANGPTL4 in adipose tissue improves glucose tolerance and attenuates atherogenesis
Aryal, B., Singh, A. K., Zhang, X., Varela, L., Rotllan, N., Goedeke, L., Chaube, B., Camporez, J.-P., Vatner, D. F., Horvath, T. L., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.97918 · Cited by 127
“clonal antibody against ANGPTL4 in mice and nonhuman primates reduced TAG levels due to modulation of LPL activity (28).”
The use of electronic health records for psychiatric phenotyping and genomics
Smoller, J. W. (2018) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32548 · Cited by 121
“…disease associations (Denny et al., 2011; Hoffmann et al., 2017), evaluate the penetrance of putative high-penetrance mutations (Van Driestetal.,2016),andidentifyallelicseriesthatcanvalidatetargetsfor SMOLLER | 7 SMOLLER drug development (Dewey et al., 2016).”
BackgroundKaltoft, M., Langsted, A., & Nordestgaard, B. G. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa172 · Cited by 122
Mysling, S., Kristensen, K. K., Larsson, M., Kovrov, O., Bensadouen, A., Jørgensen, T. J., Olivecrona, G., Young, S. G., & Ploug, M. (2016) · eLife · doi:10.7554/elife.20958 · Cited by 77
“Genome-wide association studies have shown that the common polymorphic variant ANGPTL4E15K (often denoted E40K) is linked to mild hypotriglyceridemia and reduced risk of coronary artery disease (Dewey et al., 2016; Helgadottir et al., 2016; Stitziel et al., 2016; Yin et al., 2009).”
BackgroundInfluentialAngiopoietin-like 4 promotes intracellular degradation of lipoprotein lipase in adipocytes
Dijk, W., Beigneux, A. P., Larsson, M., Bensadoun, A., Young, S. G., & Kersten, S. (2016) · Journal of Lipid Research · doi:10.1194/jlr.m067363 · Cited by 103
“CHO pgsA-745 cells were electroporated with an expression vector for Flag-tagged human ANGPTL4 (either the full-length protein hANGPTL4[1–406] or the amino-terminal domain of hANGPTL4 [1–160]) or a vector for V5tagged human LPL (or empty vector).”
BackgroundMethodOn the mechanism of angiopoietin-like protein 8 for control of lipoprotein lipase activity
Kovrov, O., Kristensen, K. K., Larsson, E., Ploug, M., & Olivecrona, G. (2019) · Journal of Lipid Research · doi:10.1194/jlr.m088807 · Cited by 116
Zhao, Y., Zhuang, Z., Li, Y., Xiao, W., Song, Z., Huang, N., Wang, W., Dong, X., Jia, J., Clarke, R., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46686-x · Cited by 117
“Cardiometabolic multimorbidity was defined as the occurrence of at least two cardiometabolic diseases, like the co-existence of ischemic heart disease and type 2 diabetes (IHD-T2D multimorbidity) and the co-existence of stroke and ischemic heart disease (IHD-stroke multimorbidity).””
Toth, P. P., Granowitz, C., Hull, M., Liassou, D., Anderson, A., & Philip, S. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.008740 · Cited by 117
Genetics Insights in the Relationship Between Type 2 Diabetes and Coronary Heart Disease
Goodarzi, M. O., & Rotter, J. I. (2020) · Circulation Research · doi:10.1161/circresaha.119.316065 · Cited by 141
Quantifying the polygenic contribution to variable expressivity in eleven rare genetic disorders
Oetjens, M. T., Kelly, M. A., Sturm, A. C., Martin, C. L., & Ledbetter, D. H. (2019) · Nature Communications · doi:10.1038/s41467-019-12869-0 · Cited by 117
Self-citationHomburger, J. R., Green, E. M., Caleshu, C., Sunitha, M. S., Taylor, R. E., Ruppel, K. M., Metpally, R. P. R., Colan, S. D., Michels, M., Day, S. M., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1606950113 · Cited by 118
“Once again, we included only missense variants and removed variants with an allele frequency greater than 1 in 2000 in the DiscovEHR exomes (Supplementary Text 1).”
BackgroundMethodInfluentialSelf-citationTriglycerides and risk of atherosclerotic cardiovascular disease: An update
Farnier, M., Zeller, M., Masson, D., & Cottin, Y. (2021) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2020.11.006 · Cited by 121
Genetics of Triglycerides and the Risk of Atherosclerosis
Dron, J. S., & Hegele, R. A. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0667-9 · Cited by 110
Khetarpal, S. A., Zeng, X., Millar, J. S., Vitali, C., Somasundara, A. V. H., Zanoni, P., Landro, J. A., Barucci, N., Zavadoski, W. J., Sun, Z., et al. (2017) · Nature Medicine · doi:10.1038/nm.4390 · Cited by 108
The application of big data to cardiovascular disease: paths to precision medicine
Leopold, J. A., Maron, B. A., & Loscalzo, J. (2020) · Journal of Clinical Investigation · doi:10.1172/jci129203 · Cited by 111
“…variants in the sterol transporter NPC1L1, which correlate with improved outcome in patients treated with anti-NPC1L1 pharmacotherapy (9, 10); and loss-of-function mutations in ANGPTL4 , which are associated with lower triglyceride levels and protection from cardiovascular disease (11, 12).”
BackgroundCBIPM Genomics Team, Abul-Husn, N. S., Regeneron Genetics Center, Soper, E. R., Odgis, J. A., Cullina, S., Bobo, D., Moscati, A., Rodriguez, J. E., Loos, R. J. F., et al. (2020) · Genome Medicine · doi:10.1186/s13073-019-0691-1 · Cited by 106
Angiopoietin-like 4 binds neuropilins and cooperates with VEGF to induce diabetic macular edema
Sodhi, A., Ma, T., Menon, D., Deshpande, M. M., Jee, K. J., Dinabandhu, A., Vancel, J., Lu, D., & Montaner, S. (2019) · Journal of Clinical Investigation · doi:10.1172/jci120879 · Cited by 104
“Interestingly, human genetics studies using carriers of a missense E40K variant of ANGPTL4 or other inactivating ANGPTL4 mutations showed lower levels of TGs and higher levels of plasma high-density lipoprotein (HDL) cholesterol and lower risk of coronary artery disease (CAD) compared with control individuals expressi…”
Precision Medicine: A New Paradigm in Therapeutics
Akhoon, N. (2021) · International Journal of Preventive Medicine · doi:10.4103/ijpvm.ijpvm_375_19 · Cited by 132
“[34] Loss of function mutation of the ANGPTL4 gene is associated with good lipid profiles and lower risk of coronary artery disease.[35] Animal models back these effects of monoclonal antibodies,[35] further supporting ANGPTL4 as a candidate drug target in coronary artery disease.”
BackgroundIncreased ANGPTL3, 4 and ANGPTL8/betatrophin expression levels in obesity and T2D
Abu-Farha, M., Al-Khairi, I., Cherian, P., Chandy, B., Sriraman, D., Alhubail, A., Al-Refaei, F., AlTerki, A., & Abubaker, J. (2016) · Lipids in Health and Disease · doi:10.1186/s12944-016-0337-x · Cited by 99
“Recent data has also linked loss of function mutations in ANGPTL4 to reduced incidences of Coronary heart disease [17, 18].”
Justice, A. E., Karaderi, T., Highland, H. M., Young, K. L., Graff, M., Lu, Y., Turcot, V., Auer, P. L., Fine, R. S., Guo, X., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0334-2 · Cited by 100
Antiinflammatory activity of ANGPTL4 facilitates macrophage polarization to induce cardiac repair
Cho, D. I., Kang, H.-J., Jeon, J. H., Eom, G. H., Cho, H. H., Kim, M. R., Cho, M., Jeong, H.-Y., Cho, H. C., Hong, M. H., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.125437 · Cited by 99
Bartlett, J., Predazzi, I. M., Williams, S. M., Bush, W. S., Kim, Y., Havas, S., Toth, P. P., Fazio, S., & Miller, M. (2016) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.115.002436 · Cited by 96
“SBP 125 (34) 118 (20) 120 (38) 125 (53) 130 (38) 118 (18) 123 (30) 130 (19) 130 (36)”
The Importance of Lipoprotein Lipase Regulation in Atherosclerosis
Kumari, A., Kristensen, K. K., Ploug, M., & Winther, A.-M. L. (2021) · Biomedicines · doi:10.3390/biomedicines9070782 · Cited by 115
“Although the mechanistic insights of ApoC-II and its association with atherosclerosis are not yet fully elucidated, further investigations in this field may lead to new therapeutic potentials aimed at ASCVD.”
BackgroundInfluentialNew insights into angiopoietin-like proteins in lipid metabolism and cardiovascular disease risk
Kersten, S. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000600 · Cited by 94
Kinetics of plasma triglycerides in abdominal obesity
Björnson, E., Adiels, M., Taskinen, M., & Borén, J. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000375 · Cited by 105
Mirshahi, U. L., Colclough, K., Wright, C. F., Wood, A. R., Beaumont, R. N., Tyrrell, J., Laver, T. W., Stahl, R. C., Golden, A. M., Goehringer, J., et al. (2022) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2022.09.014 · Cited by 104
Self-citationWang, Q., Oliver-Williams, C., Raitakari, O. T., Viikari, J., Lehtimäki, T., Kähönen, M., Järvelin, M.-R., Salomaa, V., Perola, M., Danesh, J., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa972 · Cited by 89
“Loss-of-function variants in ANGPTL4 are associated with lower triglycerides, higher HDL cholesterol, and lower CHD risk.(4) ANGPTL3 is exclusively produced in the liver and it primarily acts to inhibit LPL, although it also inhibits endothelial lipase, an enzyme more specific to hydrolysis of lipoprotein phospholipid…”
BackgroundRNA Therapeutics in Cardiovascular Precision Medicine
Laina, A., Gatsiou, A., Georgiopoulos, G., Stamatelopoulos, K., & Stellos, K. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00953 · Cited by 88
“Several lines of evidence support a beneficial metabolic profile in patients with loss-of-function genetic variants in the gene encoding ANGPTL3 and ANGPTL4 expressed as low levels of plasma LDL cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides, and reduced insulin resistance (Robciuc et al., 2013…”
BackgroundKersten, S. (2021) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000789 · Cited by 83
“One could wonder, though, why carrier status of loss-of-function variants in ANGPTL4, which is similarly associated with increased LPL activity and enhanced plasma triglyceride clearance, is not significantly associated with LDL-C [42].”
BackgroundAngiopoietin-like 4 directs uptake of dietary fat away from adipose during fasting
Cushing, E. M., Chi, X., Sylvers, K. L., Shetty, S. K., Potthoff, M. J., & Davies, B. S. J. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.06.007 · Cited by 88
“Thus, it has been proposed that targeting ANGPTL4 activity may be a useful way to therapeutically increase LPLdriven triglyceride clearance, lower plasma triglycerides, and lower the risk of coronary disease [11,12,14,15].”
BackgroundFasting, non-fasting and postprandial triglycerides for screening cardiometabolic risk
Keirns, B. H., Sciarrillo, C. M., Koemel, N. A., & Emerson, S. R. (2021) · Journal of Nutritional Science · doi:10.1017/jns.2021.73 · Cited by 86
“APOC3, ANGPTL4) are associated with reduced triglycerides and lower risk of CVD((60,61)).”
BackgroundNomura, A., Won, H.-H., Khera, A. V., Takeuchi, F., Ito, K., McCarthy, S., Emdin, C. A., Klarin, D., Natarajan, P., Zekavat, S. M., et al. (2017) · Circulation Research · doi:10.1161/circresaha.117.311145 · Cited by 86
“mellitus, n (%) 8 (24) 5069 (20) 5 (31) 4126 (17) 8 (44) 4343 (48) 78 (64) 8568 (55) 9 (42) 917 (35) 16 (21) 2174 (23)”
Self-citationNew, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins
Kim, K., Ginsberg, H. N., & Choi, S. H. (2022) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0198 · Cited by 80
“A previous study showed that the carriers of inactivating mutations in the ANGPTL4 gene had lower levels of plasma TG and a lower risk of coronary artery disease, compared with the noncarriers [95].”
BackgroundResultThe Role of Adipocytokines in Coronary Atherosclerosis
Liberale, L., Bonaventura, A., Vecchié, A., Casula, M., Dallegri, F., Montecucco, F., & Carbone, F. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0644-3 · Cited by 95
Ruscica, M., Zimetti, F., Adorni, M. P., Sirtori, C. R., Lupo, M. G., & Ferri, N. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104653 · Cited by 82
Endothelial cell–cardiomyocyte crosstalk in diabetic cardiomyopathy
Wan, A., & Rodrigues, B. B. (2016) · Cardiovascular Research · doi:10.1093/cvr/cvw159 · Cited by 95
“have suggested that patients with inactivating mutations in ANGPTL4 have lower levels of TGs and a lower risk of coronary artery disease, linking TG to cardiac disease.(154,155) Cellular crosstalk 179”
BackgroundSagris, Μ., Apostolos, A., Theofilis, P., Ktenopoulos, N., Katsaros, O., Tsalamandris, S., Tsioufis, K. P., Toutouzas, K. P., & Tousoulis, D. (2024) · Biomedicines · doi:10.3390/biomedicines12040802 · Cited by 96
“Indeed, Dewey et al. have shown that monoclonal antibodies inhibit ANGPLT4 in mice and monkeys and reduce triglyceride serum levels [120].”
BackgroundFialkow, J. (2016) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-016-0170-7 · Cited by 80
“More recently, genetic studies have revealed that inactivating mutations in the gene encoding ANGPTL4 (a regulatory factor in triglyceride metabolism) are associated with lower triglyceride levels and lower risk of coronary artery disease [25, 26].”
BackgroundTriglyceride and Triglyceride-Rich Lipoproteins in Atherosclerosis
Zhang, B., Yin, F., Qiao, Y.-N., & Guo, S. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.909151 · Cited by 104
Lotta, L. A., Stewart, I. D., Sharp, S. J., Day, F. R., Burgess, S., Luan, J., Bowker, N., Cai, L., Li, C., Wittemans, L. B. L., et al. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2018.2866 · Cited by 72
“Age at baseline, mean (SD), y 57 (8) 55 (7) 52 (9) 59 (9)”
Kristensen, K. K., Leth-Espensen, K. Z., Mertens, H. D. T., Birrane, G., Meiyappan, M., Olivecrona, G., Jørgensen, T. J. D., Young, S. G., & Ploug, M. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1920202117 · Cited by 72
Genetics of Lipid and Lipoprotein Disorders and Traits
Dron, J. S., & Hegele, R. A. (2016) · Current Genetic Medicine Reports · doi:10.1007/s40142-016-0097-y · Cited by 77
Metadata
- Authors
- Dewey, F. E., Gusarova, V., O’Dushlaine, C., Gottesman, O., Trejos, J., Hunt, C., Van Hout, C. V., Habegger, L., Buckler, D., Lai, K.-M. V., Leader, J. B., Murray, M. F., Ritchie, M. D., Kirchner, H. L., Ledbetter, D. H., Penn, J., Lopez, A., Borecki, I. B., Overton, J. D., Reid, J. G., Carey, D. J., Murphy, A. J., Yancopoulos, G. D., Baras, A., Gromada, J., & Shuldiner, A. R.
- Affiliations
- Regeneron (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-03-24
- Volume
- 374
- Issue
- 12
- Pages
- 1123-1133
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4900689
- OpenAlex
- W2323589075
- Cited by
- 497
- References
- 40
- Citations by year
- 2026: 33 · 2025: 40 · 2024: 38 · 2023: 36 · 2022: 41 · 2021: 63 · 2020: 52 · 2019: 51 · 2018: 53 · 2017: 57 · 2016: 33
- FWCI
- 53.39
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK072488)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- ANGPTL4, loss-of-function mutations, coronary artery disease, triglycerides, HDL cholesterol, lipoprotein lipase, genetic variants, monoclonal antibody inhibition, serum lipids, genetic association studies
- MeSH terms
- Angiopoietin-Like Protein 4, Aged, Animals, Cholesterol, Coronary Artery Disease, Disease Models, Animal, Female, Heterozygote, Humans, Macaca mulatta, Male, Middle Aged, Mutation, Risk Factors, Triglycerides, Gene Silencing, Angiopoietins, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.